PARP Inhibitors in the Treatment of Ovarian Cancer
This Peer Exchange Webinar will provide insights into use of PARP inhibitors in the treatment of ovarian cancer.
Use of PARP inhibitors in the treatment of ovarian cancer is a promising option for many patients with advanced or recurrent disease. With multiple options available in this drug class, understanding supporting data for these products is sometimes not enough. Practical experience is incredibly valuable help ensure their optimal and appropriate use.
This Peer Exchange Webinar will provide insights into both of these subjects. Our panel of experts will also frame this conversation based on experiences from multiple practice types and how those perspectives affect clinical decision-making as well as application.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
FDA Approves Bosaya and Aukelso, Biosimilars to Reference DenosumabSeptember 17th 2025
Understanding the Risk of Second Primary Cancers After Early Breast CancerSeptember 16th 2025
